drugset
drugset / Trial / NCT02703636

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

NCT02703636 ↗

Phase 4 Completed 118 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of rivastigmine patch with 1-step titration on cognitive function measured as change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE) in mild to moderate Alzheimer's disease (AD) patients who failed to benefit from other cholinesterase inhibitors (ChEIs).

Timeline

Start
2016-05-09
Primary completion
2018-05-07
Completion
2018-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivastigmine Small molecule 18 mg —

Indications

No indication recorded.